Literature DB >> 25017793

Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes during diabetic nephropathy.

Pan Gao1, Xian-Fang Meng2, Hua Su1, Fang-Fang He1, Shan Chen1, Hui Tang1, Xiu-Juan Tian1, Di Fan1, Yu-Mei Wang1, Jian-She Liu1, Zhong-Hua Zhu1, Chun Zhang3.   

Abstract

Numerous studies have shown that the NALP3 inflammasome plays an important role in various immune and inflammatory diseases. However, whether the NALP3 inflammasome is involved in the pathogenesis of diabetic nephropathy (DN) is unclear. In our study, we confirmed that high glucose (HG) concentrations induced NALP3 inflammasome activation both in vivo and in vitro. Blocking NALP3 inflammasome activation by NALP3/ASC shRNA and caspase-1 inhibition prevented IL-1β production and eventually attenuated podocyte and glomerular injury under HG conditions. We also found that thioredoxin (TRX)-interacting protein (TXNIP), which is a pro-oxidative stress and pro-inflammatory factor, activated NALP3 inflammasome by interacting with NALP3 in HG-exposed podocytes. Knocking down TXNIP impeded NALP3 inflammasome activation and alleviated podocyte injury caused by HG. In summary, the NALP3 inflammasome mediates podocyte and glomerular injury in DN, moreover, TXNIP participates in the formation and activation of the NALP3 inflammasome in podocytes during DN, which represents a novel mechanism of podocyte and glomerular injury under diabetic conditions.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetic nephropathy; NALP3 inflammasome; Podocyte; TXNIP

Year:  2014        PMID: 25017793     DOI: 10.1016/j.bbamcr.2014.07.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

1.  MAD2B promotes tubular epithelial-to-mesenchymal transition and renal tubulointerstitial fibrosis via Skp2.

Authors:  Hui Tang; Di Fan; Chun-Tao Lei; Chen Ye; Pan Gao; Shan Chen; Xian-Fang Meng; Hua Su; Chun Zhang
Journal:  J Mol Med (Berl)       Date:  2016-08-03       Impact factor: 4.599

2.  Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy.

Authors:  Anu Shah; Ling Xia; Elodie A Y Masson; Chloe Gui; Abdul Momen; Eric A Shikatani; Mansoor Husain; Susan Quaggin; Rohan John; I G Fantus
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

Review 3.  Role of the Immune System in Diabetic Kidney Disease.

Authors:  Fionnuala B Hickey; Finian Martin
Journal:  Curr Diab Rep       Date:  2018-03-12       Impact factor: 4.810

Review 4.  The Nucleotide Oligomerization Domain-Like Receptors in Kidney Injury.

Authors:  Xiaojie Wang; Fan Yi
Journal:  Kidney Dis (Basel)       Date:  2016-03-08

Review 5.  Mechanisms of hemorrhagic cystitis.

Authors:  Subhash Haldar; Christopher Dru; Neil A Bhowmick
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

Review 6.  Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy.

Authors:  Wenli Zhao; Le Zhou; Petr Novák; Xian Shi; Chuang Biao Lin; Xiao Zhu; Kai Yin
Journal:  J Diabetes Res       Date:  2022-06-09       Impact factor: 4.061

Review 7.  Innate immunity in diabetes and diabetic nephropathy.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

8.  NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia.

Authors:  Pan Gao; Fang-Fang He; Hui Tang; Chun-Tao Lei; Shan Chen; Xian-Fang Meng; Hua Su; Chun Zhang
Journal:  J Diabetes Res       Date:  2015-03-05       Impact factor: 4.011

Review 9.  Innate immunity in diabetic kidney disease.

Authors:  Sydney C W Tang; Wai Han Yiu
Journal:  Nat Rev Nephrol       Date:  2020-01-15       Impact factor: 28.314

10.  High Glucose and Lipopolysaccharide Prime NLRP3 Inflammasome via ROS/TXNIP Pathway in Mesangial Cells.

Authors:  Hong Feng; Junling Gu; Fang Gou; Wei Huang; Chenlin Gao; Guo Chen; Yang Long; Xueqin Zhou; Maojun Yang; Shuang Liu; Shishi Lü; Qiaoyan Luo; Yong Xu
Journal:  J Diabetes Res       Date:  2016-01-05       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.